• Principal Investigator
  • Male

Dr. M.F. Bijlsma

Position: Associate professor (UHD)
Main activities: Research
Specialisation: The biology of pancreatic cancer
foto M.F. Bijlsma is one of the AMC Principal Investigators
Focus of research:

My lab studies the biology underlying the growth and therapy resistance of pancreatic cancer. Models in my lab range from cell culture systems, mouse experiments, biobanking and the analysis of predictive and prognostic markers and profiles in large cohorts.


One of the most typical features of pancreatic tumors is the abundance of non-cancerous cells and material – the stroma. The stroma exerts both tumor-promoting as well as -limiting properties. We aim to identify which signals mediate critical tumor-stroma crosstalk, and whether we can use this to target tumor growth and drug resistance. In addition, we develop blood-borne markers to stratify patients for stroma-targeting treatments.


Many events that shape the developing embryo are regulated by the Hedgehog proteins. In the adult body, activity of these proteins is limited, but reactivation of the pathway is thought to contribute to pancreatic cancer. Several lines of research in my lab deal with the production and transport, but also the reception and interpretation of this ligand.


To construct the relevant experimental models needed to study pancreatic cancer, I have founded the AMC biobank pancreatic carcinoma – BioPAN. For this biobank we accrue and store blood samples, tissue, and clinical data. Analyses on these materials include expression profiling and measurements of serum markers. BioPAN closely collaborates with the nation-wide PancreasParel biobank. Our expression profiling efforts have enabled us to identify subgroups of patients that differ in their clinical outcome and other clinically important parameters.


The lethality of pancreatic cancer relies on the presence of so called cancer stem cells. Current tools to identify these cells have serious shortcomings. We have adapted tracing methods to trace the offspring of a single cell in tumors grown from these cells. These allow us to study the population of cancer stem cells that are thought to contribute to pancreatic cancer growth.
 

AMC themes: Oncology
Departments: Center of Experimental and Molecular Medicine
Bijlsma MF, Sadanandam A, Tan P, Vermeulen L, Molecular subtypes in cancers of the gastrointestinal tract. NAT REV GASTRO HEPAT 2017;14 (6):333-342 [PubMed]
Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF , van Oijen MGH, van Laarhoven HWM, Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. BBA-BIOENERGETICS 2017;1868 (2):394-403 [PubMed]
Creemers A, ter Veer E, de Waal L, Lodder P, Hooijer GKJ, van Grieken NCT, Bijlsma MF , Meijer SL, van Oijen MGH, van Laarhoven HWM, Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis. SCI REP-UK 2017;7 (1):3135 [PubMed]
Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM, Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition. GASTROENTEROLOGY 2017;153 (1):63-76.e14 [PubMed]
Le Large TYS , Bijlsma MF , Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR, Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. SEMIN CANCER BIOL 2017;44:153-169 [PubMed]
Veenstra VL, Damhofer H, Waasdorp C, Steins A, Kocher HM, Medema JP, van Laarhoven HW, Bijlsma MF, Stromal SPOCK1 supports invasive pancreatic cancer growth. MOL ONCOL 2017;11 (8):1050-1064 [PubMed]
Ebbing EA, Medema JP, Damhofer H, Meijer SL, Krishnadath KK, van Berge Henegouwen MI, Bijlsma MF, van Laarhoven HWM, ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. ONCOTARGET 2016;7 (9):10243-10254 [PubMed]
Le Large TYS, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, Giovannetti E, Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. EXPERT REV MOL DIAGN 2016;16 (7):733-736 [PubMed]
Mariani LE, Bijlsma MF, Ivanova AI, Suciu SK, Kahn RA, Caspary T, Arl13b regulates Shh signaling from both inside and outside the cilium. MOL BIOL CELL 2016;27 (23):3780-3790 [PubMed]
van Neerven SM, Tieken M, Vermeulen L, Bijlsma MF, Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity. MOL CELL ONCOL 2016;3 (2):UNSP e1098791 [PubMed]
Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PHM, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Małecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li D, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT, Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. ONCOTARGET 2016;7 (41):66328-66343 [PubMed]
Bijlsma MF, van Laarhoven HWM, The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. CANCER METAST REV 2015;34 (1):97-114 [PubMed]
Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, Landi S, Lu L, Malecka-Panas E, Mambrini A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlow I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashist YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP, Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. NAT GENET 2015;47 (8):911-916 [PubMed]
Damhofer H. Opening new doors: Hedgehog signaling and the pancreatic cancer stroma. S.l.: s.n.; 2015. 191p. ISBN 978-94-6182-545-2 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Medema JP; copromotor(s): Bijlsma MF)
Damhofer H, Ebbing EA, Steins A, Welling L, Tol JA, Krishnadath KK, van Leusden T, van de Vijver MJ, Besselink MG, Busch OR, van Berge Henegouwen MI, van Delden O, Meijer SL, Dijk F, Medema JP, van Laarhoven HW, Bijlsma MF, Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. J TRANSL MED 2015;13 (1):115 [PubMed]
Damhofer H, Veenstra VL, Tol JAMG, van Laarhoven HWM, Medema JP, Bijlsma MF, Blocking Hedgehog release from pancreatic cancer cells increases paracrine signaling potency. J CELL SCI 2015;128 (1):129-139 [PubMed]
Klaassen R, Bennink RJ, van Tienhoven G, Bijlsma MF, Besselink MGH, van Berge Henegouwen MI, Wilmink JW, Nederveen AJ, Windhorst AD, Hulshof MCCM, van Laarhoven HWM, Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer. RADIOTHER ONCOL 2015;116 (1):94-99 [PubMed]
Rosati A, Basile A, D'Auria R, d'Avenia M, de Marco M, Falco A, Festa M, Guerriero L, Iorio V, Parente R, Pascale M, Marzullo L, Franco R, Arra C, Barbieri A, Rea D, Menichini G, Hahne M, Bijlsma M, Barcaroli D, Sala G, di Mola FF, di Sebastiano P, Todoric J, Antonucci L, Corvest V, Jawhari A, Firpo MA, Tuveson DA, Capunzo M, Karin M, de Laurenzi V, Turco MC, BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. NAT COMMUN 2015;6:8695 [PubMed]
Alfaro AC, Roberts B, Kwong L, Bijlsma MF, Roelink H, Ptch2 mediates the Shh response in Ptch1(-/-) cells. DEVELOPMENT 2014;141 (17):3331-3339 [PubMed]
Kwong L, Bijlsma MF, Roelink H, Shh-mediated degradation of Hhip allows cell autonomous and non-cell autonomous Shh signalling. NAT COMMUN 2014;5:4849 [PubMed]
Damhofer H, Medema JP, Veenstra VL, Badea L, Popescu I, Roelink H, Bijlsma MF, Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma. MOL ONCOL 2013;7 (6):1031-1042 [PubMed]
de Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, Rodermond H, van der Heijden M, van Noesel CJM, Tuynman JB, Dekker E, Markowetz F, Medema JP, Vermeulen L, Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. NAT MED 2013;19 (5):614-618 [PubMed]
Bijlsma MF, Damhofer H, Roelink H, Hedgehog-Stimulated Chemotaxis Is Mediated by Smoothened Located Outside the Primary Cilium. SCI SIGNAL 2012;5 (238):ra60 [PubMed]
Hindriksen S, Bijlsma MF, Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. CANCERS 2012;4 (4):989-1035 [PubMed]
Queiroz KCS, Bijlsma MF, Tio RA, Zeebregts CJ, Dunaeva M, Ferreira CV, Fuhler GM, Kuipers EJ, Alves MM, Rezaee F, Spek CA, Peppelenbosch MP, Dichotomy in Hedgehog Signaling between Human Healthy Vessel and Atherosclerotic Plaques. MOL MED 2012;18 (7):1122-1127 [PubMed]
Bijlsma MF, Roelink H, Non-cell-autonomous signaling by Shh in tumors: challenges and opportunities for therapeutic targets. EXPERT OPIN THER TAR 2010;14 (7):693-702 [PubMed]
Bijlsma MF, Spek CA, The Hedgehog morphogen in myocardial ischemia-reperfusion injury. EXP BIOL MED 2010;235 (4):447-454 [PubMed]
Brüggemann LW, Queiroz KCS, Zamani K, van Straaten A, Spek CA, Bijlsma MF, Assessing the efficacy of the hedgehog pathway inhibitor vitamin D3 in a murine xenograft model for pancreatic cancer. CANCER BIOL THER 2010;10 (1):79-88 [PubMed]
Queiroz KCS, Tio R, Zeebregts C, Bijlsma MF, Zijlstra F, Badlou B, de Vries M, Ferreira CV, Spek CA, Peppelenbosch MP, Rezaee F, Human Plasma Very Low Density Lipoprotein Carries Indian Hedgehog. J PROTEOME RES 2010;9 (11):6052-6059 [PubMed]
Spek CA, Bijlsma MF, Queiroz KCS, Canonical Hedgehog signaling drives proangiogenic responses in endothelial cells. CELL CYCLE 2010;9 (9):1683 [PubMed]
Bijlsma MF, Groot AP, Oduro JP, Franken RJ, Schoenmakers SHHF, Peppelenbosch MP, Spek CA, Hypoxia induces a hedgehog response mediated by HIF-1alpha. J CELL MOL MED 2009;13 (8B):2053-2060 [PubMed]
Borensztajn K, Bijlsma MF, Reitsma PH, Peppelenbosch MP, Spek CA, Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation. THROMB RES 2009;124 (2):219-225 [PubMed]
Hovius JWR, Bijlsma MF, van der Windt GJW, Wiersinga WJ, Boukens BJD, Coumou J, Oei A, de Beer R, de Vos AF, van 't Veer C, van Dam AP, Wang P, Fikrig E, Levi MM, Roelofs JJTH, van der Poll T, The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi. PLOS PATHOG 2009;5 (5):e1000447 [PubMed]
Bijlsma MF. Novel mechanism and functions for hedgehog signaling in development and disease. s.l.: s.n.; 2008. 107p. ISBN 9789064642821 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Peppelenbosch MP; copromotor(s): Spek CA)
Bijlsma MF, Leenders PJA, Janssen BJA, Peppelenbosch MP, ten Cate H, Spek CA, Endogenous hedgehog expression contributes to myocardial ischemia-reperfusion-induced injury. EXP BIOL MED 2008;233 (8):989-996 [PubMed]
Bijlsma MF, Peppelenbosch MP, Spek CA, (Pro-)vitamin D as treatment option for hedgehog-related malignancies. MED HYPOTHESES 2008;70 (1):202-203 [PubMed]
Bijlsma MF, Peppelenbosch MP, Spek CA, Roelink H, Leukotriene synthesis is required for hedgehog-dependent neurite projection in neuralized embryoid bodies but not for motor neuron differentiation. STEM CELLS 2008;26 (5):1138-1145 [PubMed]
Lipinski RJ, Bijlsma MF, Gipp JJ, Podhaizer DJ, Bushman W, Establishment and characterization of immortalized Gli-null mouse embryonic fibroblast cell lines. BMC CELL BIOL 2008;9:49 [PubMed]
Bijlsma MF, Borensztajn KS, Roelink H, Peppelenbosch MP, Spek CA, Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. CELL SIGNAL 2007;19 (12):2596-2604 [PubMed]
Borensztajn KS, Bijlsma MF, Groot AP, Bruggemann LW, Versteeg HH, Reitsma PH, Peppelenbosch MP, Spek CA, Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. EXP CELL RES 2007;313 (12):2622-2633 [PubMed]
Slofstra SH, Bijlsma MF, Groot AP, Reitsma PH, Lindhout T, ten Cate H, Spek CA, Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. BLOOD 2007;110 (9):3176-3182 [PubMed]
Bijlsma MF, Peppelenbosch MP, Spek CA, A dual role for 7-dehydrocholesterol reductase in regulating Hedgehog signalling?. DEVELOPMENT 2006;133 (20):3951; author reply 3952-3951; author reply 3953 [PubMed]
Bijlsma MF, Peppelenbosch MP, Spek CA, Hedgehog morphogen in cardiovascular disease. CIRCULATION 2006;114 (18):1985-1991 [PubMed]
Bijlsma MF, Spek CA, Peppelenbosch MP, Hedgehog turns lipoproteins into Janus-faced particles. TRENDS CARDIOVAS MED 2006;16 (7):217-220 [PubMed]
Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP, Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLOS BIOL 2006;4 (8):e232-1410 [PubMed]
de Jonge WJ, van der Zanden EP, O The F, Bijlsma MF , van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, van den Wijngaard RM, Boeckxstaens GE, Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway (vol 6, pg 844, 2005). NAT IMMUNOL 2005;6 (9):954
de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, van den Wijngaard RM, Boeckxstaens GE, Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. NAT IMMUNOL 2005;6 (8):844-851 [PubMed]
Bijlsma MF, Spek CA, Peppelenbosch MP, Hedgehog: an unusual signal transducer. BIOESSAYS 2004;26 (4):387-394 [PubMed]
Key publications

Bijlsma MF, Damhofer H, Roelink H, Hedgehog-Stimulated Chemotaxis Is Mediated by Smoothened Located Outside the Primary Cilium. SCI SIGNAL 2012;5 (238):ra60 [PubMed]
Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP, Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLOS BIOL 2006;4 (8):e232-1410 [PubMed]
Bijlsma MF, van Laarhoven HWM, The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. CANCER METAST REV 2015;34 (1):97-114 [PubMed]
Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, Landi S, Lu L, Malecka-Panas E, Mambrini A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlow I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashist YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP, Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. NAT GENET 2015;47 (8):911-916 [PubMed]


All Publications

Curriculum Vitae

 

2017                 Fakultetsopponent thesis defence, Karolinska Institutet, Sweden
2016 – present   Program leader of the Biomarker program AMC/VUmc Alliance Cancer Center Amsterdam.
2016                 Appointed AMC Principal Investigator.
2015                 Doctorate thesis committee member, University of Amsterdam
2014 – present   Member, Research Network PANDoRA, DKFZ at Heidelberg, Germany.
2014 – present   Editorial board member Journal of Clinical and Translational Research.
2014                 Doctorate thesis committee member,Univ. of Montpellier, France.
2012 – present   Co-coordinator of BioOES, AMC esophageal carcinoma biobank.
2011 – present   Founder and coordinator of BioPAN, AMC pancreatic biobank.
2011 – present   Member of the Dutch Pancreatic Cancer Group (DPCG).
2011                  Doctorate thesis committee member, University of Amsterdam
2010 – present   Group leader at Academic Medical Center, Amsterdam
2009 – present   Reviewer for various funding agencies: AICR, Skolkovo Foundation, Kom op Tegen Kanker, ZonMW.
2006 – present   Reviewer for journals: Clinical Cancer Research, Oncogenesis, Oncotarget, Cell Death and Differentiation, Biochimica et Biophysica Acta, Journal of Cellular and Molecular Medicine, Journal of Cell Science, PLoS One, The Open Stem Cell Journal, Journal of Neurology and Neurological Disorders, Molecular and Cellular Neuroscience, Experimental Biology and Medicine, Expert Opinion On Therapeutic Targets, Journal of Cellular and Molecular Medicine, Molecular Pharmacology, International Journal of Cancer, Cell Proliferation, Journal of Developmental Biology, Current Genomics, AJP:Endocrinology and Metabolism, Journal of Investigative Dermatology, The FASEB Journal, EMBO Molecular Medicine, Nature Communications.

 

Research programmes

The biology of pancreatic cancer

For the next 2-3 years I will further my lab’s expression profiling efforts and establish international consensus subtypes for pancreatic cancer with my collaborators. These molecular subtypes will be used as the standard framework to study tumor biology in the context of heterogeneity.


The serum markers for pancreatic cancer stroma developed in my group are tested in relevant external trial cohorts, and this will be expanded to clinical trials in the AMC, preferably in interventional studies.


Additional research lines aim to develop and biologically validate non-invasive imaging of pancreatic cancer, with a strong focus on the tumor stroma.


Importantly, I will establish how the individual factors that contribute to the pancreatic cancer (stroma, cancer stem cells, intertumor heterogeneity) interact to confer highly lethal tumor characteristics. My group has now accrued a unique set of tools to address these connections in unison.


Research topics from my lab are extended to other tumor types through my close collaborations with other PIs in the AMC. These tumor types include esophageal cancer, colon cancer and basal cell carcinoma.

See also Focus of research section. 

Faculty
Dr. M.F. Bijlsma

PhD Students
A. Creemers
Drs. E.A. Ebbing
R. Klaassen MSc
Drs. T.Y.S. Le Large MD (VUmc)
S.C. Lodestijn
M.G. Mackelenbergh
S. Schokker
Drs. A. Steins
M. Strijker
C. Tekin
Drs. V.L. Veenstra

Prof. dr. J.P. Medema (Cell death induction and resistance in tumor cells)

Other research related activities
  • Membership of editorial board / Editorship, JOURNAL OF CLINICAL AND TRANSLATIONAL RESEARCH
Current research funding
  • AMC
  • KWF Kankerbestrijding
  • Stichting AMC Foundation (Vrijgesteld)